Indivior Pharmaceuticals (INDV) Common Equity (2022 - 2025)
Historic Common Equity for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to -$207.0 million.
- Indivior Pharmaceuticals' Common Equity fell 2395.21% to -$207.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$207.0 million, marking a year-over-year decrease of 2395.21%. This contributed to the annual value of -$337.0 million for FY2024, which is 8315.22% down from last year.
- According to the latest figures from Q3 2025, Indivior Pharmaceuticals' Common Equity is -$207.0 million, which was down 2395.21% from -$257.0 million recorded in Q2 2025.
- Indivior Pharmaceuticals' Common Equity's 5-year high stood at $117.0 million during Q2 2023, with a 5-year trough of -$337.0 million in Q4 2024.
- Its 4-year average for Common Equity is -$127.6 million, with a median of -$167.0 million in 2024.
- Within the past 5 years, the most significant YoY rise in Indivior Pharmaceuticals' Common Equity was 2395.21% (2025), while the steepest drop was 295000.0% (2025).
- Indivior Pharmaceuticals' Common Equity (Quarter) stood at $51.0 million in 2022, then plummeted by 460.78% to -$184.0 million in 2023, then plummeted by 83.15% to -$337.0 million in 2024, then surged by 38.58% to -$207.0 million in 2025.
- Its Common Equity stands at -$207.0 million for Q3 2025, versus -$257.0 million for Q2 2025 and -$285.0 million for Q1 2025.